The US FDA has approved a new non-opioid painkiller, Journavx, by Vertex Pharmaceuticals, which targets pain signals before reaching the brain to provide relief for moderate to severe pain without the addictive potential of opioids. Clinical trials showed effectiveness in reducing post-surgery pain, marking an important milestone in acute pain management amidst the opioid crisis in the US. Priced at $15.50 per capsule, Journavx is the first new class of pain medicine approved in over 20 years, offering hope for the 80 million Americans prescribed pain medication annually.
Full Article
Agentification is one of the top tech trends of 2025. Here is what you need to know
As AI evolves, the key trend shaping the technological landscape in 2025 is "agentification," where AI systems operate as autonomous agents. This shift improves efficiency, decision-making, and adaptability in industries by allowing AI agents to interact and collaborate independently. Superagents, coordinating multiple AI models, are emerging as decision-makers to optimize processes and drive transformative changes in business operations. Full Article
Read more